MKI67 and neuroendocrine carcinoma: Temozolomide with or without capecitabine and bevacizumab has also recently been reported to be effective in a cohort of 25 patients with NEC, especially in NEC with a Ki-67 index of <60%, after progression on cisplatin-based chemotherapy [8].